Locations
Copenhagen, Denmark · Lyngby, Denmark
industry
Biotechnology
Size
11-50 employees
Stage
Series A
founded in
2017
Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of Cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcomes, increased morbidity, prolonged hospitalization, and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus—simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently, and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.
Something looks off?